Tirzepatide 12.5 mg KwikPen is a once-weekly injectable medication used for the management of type 2 diabetes and, in certain approvals, for chronic weight management. As a dual GIP and GLP-1 receptor agonist, it enhances insulin secretion when blood glucose levels are elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite. The 12.5 mg dose is a higher step-up maintenance dose used after gradual titration to achieve stronger blood sugar control and greater weight reduction. In addition to lowering HbA1c, it may also improve metabolic parameters such as body weight and cardiovascular risk factors. Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite, and it should be used under medical supervision.